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The Pathophysiology of Melanoma
Dianna Lauer RN, BSN
Otterbein University, Westerville, Ohio

Introduction

The patient with Melanoma

There are many types of skin cancer
prevalent in the world today. The three
most common types of skin cancer are
basal cell carcinoma, squamous cell
carcinoma, and melanoma (Watson et al,
2015). This poster presentation will
focus on the skin cancer known as
melanoma. In the words of Hawryluk &
Tsao (2014), “Melanoma is an aggressive
malignancy borne of melanocytes, the
pigment-generating cells of the skin”. In
2013, malignant melanoma had an
estimated 76, 690 new cases in the
United States, with 9,480 deaths, that
accounts for sixty percent of deaths from
skin cancers (Hawryluk & Tsao, 2014).
Melanoma has shown an “increase of 36% over the last few decades, making
this one of the fastest growing cancers
worldwide” (Liu et al, p. 1, 2014).
Melanoma is now a common
occurrence in everyday practice. Nurse
practitioners and physicians need to be
aware of risk factors, keep watch on
nevi, and consult the correct
dermatological physicians if there is
worry of melanoma. Within this poster
presentation we will dive into the
pathophysiology of melanoma including
a patient scenario, with risk factors, sign
and symptoms, and implications of
nursing care.

A 50 year old Caucasian female, with blonde hair and fair skin presented to the
office for a routine physical exam. The patient has a family history of melanoma and
has been visiting the office every six months due to recurring basal cell lesions. A nevi
on the right dorsal forearm has been under watch for a year now, with no change or
issue. The practitioner suggest to remove the nevi for biopsy due to the risk factors
the patient has.
A punch biopsy is done on the nevi and the pathology report confirms melanoma
stage II. A wide excision of the right forearm with sentinel lymph node biopsy is
done. The pathology report for the sentinel lymph biopsy comes back negative for
metastasis. The patient continues to follow up with the practitioner every three to six
months.
Four years down the road the patient discovers a lump under the right axilla. The
patient is sent to a surgeons office for a fine needle aspiration to confirm pathology.
The pathology report confirms malignancy. A biopsy reports recurrent metastatic
melanoma stage IIIB. A PET scan is ordered and confirms malignancy contained to the
right axilla region.
The patient is scheduled for dissection of the right axillary lymph nodes.
Approximately eighteen lymph nodes were removed, with three positive lymph nodes
showing melanoma. The patient is then recommended for adjuvant therapy.
* Real patient experience, posted with permission*

Signs and Symptoms
•
Change in existing mole
•
New spot or patch on the skin
•
A spot that looks like changing freckle/age spot
•
Dark streak under fingernail/toenail
•
Band of darker skin around finger/toenail
•
Slowly growing patch of thick skin that looks like a scar
(American Academy of Dermatology, 2018)

Clinical Manifestations & Staging

Stage
0
I
II
IIIA
IIIB

IIIC

IIID
IV

(American Cancer Society, 2019).
Description
confined to the epidermis (also known as melanoma in situ)
No more than 2 mm thick and may or may not be ulcerated. Has not spread to nearby lymph nodes or to distant sites
atleast 1.01 mm and may be thicker than 4.0 mm. May or may not be ulcerated. Has not spread to nearby lymph nodes
or to distant sites
no more than 2.0 mm thick. May or may not be ulcerated. Has spread to 3 or less lymph node(s) but is so small It can
only be seen under a microscope. Has not spread to distant sites
no sign of the primary cancer AND- Has spread to only one lymph node –OR- has spread to small areas of nearby skin
but has not spread to distant sites. OR the cancer is no more than 4.0 mm thick. May or may not be ulcerated -AND- has
spread to only one lymph node -OR- has spread to very small areas of nearby skin -OR- has spread to two or three lymph
nodes but has not spread to distant sites.
no sign of primary cancer AND- has spread to one or more lymph node -OR- has spread to very small areas of nearby
skin -OR- has spread to any lymph nodes that are clumped together. Has not spread to distant sites. OR no more than
4.0 mm thick. May or may not be ulcerated AND- has spread to one or more lymph nodes -OR- has spread to very small
areas of nearby skin -OR- has spread to lymph nodes that are clumped together. It has not spread to distant sites OR is
between 2.1 and 4.0 mm OR thicker than 4.0 mm. May or may not be ulcerated AND- spread to one or more lymph
nodes -OR- spread to very small areas of nearby skin -OR- has spread to lymph nodes that are clumped together. Has
not spread to distant sites. OR is thicker than 4.0 mm and is ulcerated AND- has spread to no more than 3 lymph nodes OR- has spread to very small areas of nearby skin. Has not spread to distant sites
Thicker than 4.0 mm and is ulcerated AND- has spread to very small areas of nearby skin -OR- has spread to lymph
nodes that are clumped together. Has not spread to distant sites.
Any thickness and may or may not be ulcerated. May or may not have spread to nearby lymph nodes. Has spread to
distant lymph nodes or organs such as the lungs, liver, or brain.
Staging involves the size, degree of local invasion, and the extent of where it has spread
(McCance et al, p. 1204, 2018).

Significance of Pathophysiology

Underlying Pathophysiology

Early recognition and treatment of
melanoma is crucial. When caught in the
early stages melanoma is easily treatable.
When mutations occur is when things get
tricky for the practitioner.
UV exposure and age are the biggest
contributors to melanoma ( Watson et al,
2015). With practitioners knowing this,
they must take time to evaluate the
entirety of the skin, watch for any
change, as well as be responsible for
educating the patient on risk factors and
signs and symptoms of melanoma
(Chang et al, 2014).

Melanoma can develop in an existing mole or look like a new mole
(American Academy of Dermatology 2018)
Melanocytes can be found on the epidermis of the skin. Melanocytes are responsible
for producing the pigment melanin, which gives the skin its color. Cutaneous melanoma
is caused by malignant neoplasms of the melanoctyes (Liu et al, 2014).
The etiology and pathogenesis of melanoma can be explained by Ultraviolet(UV)
radiation, melanocytic nevi, and molecular changes associated with malignant
melanoma. It is known that “one or more blistering sunburn during childhood or
adolescence more than doubles the risk for melanoma later in life” (Liu et al, p. 3,
2014). UV radiation can make DNA mutations occur, forming pyrimidine dimers or
deamination of cystosine into thymidine (Liu et al, 2014).
Another etiology are melanocytic nevi. Nevi, or moles, are completely benign lesions
concentrated with a large amount of melanocytes which give them a darker
pigmentation on the skin. When nevi begin to change in shape, color, or texture we
begin to worry that malignant melanoma may be present (Liu et al, 2014). Catching the
nevi in this early phase results in an extremely high survival rate. Practitioners should
use the ABCDE’s of melanoma. This looks at (A) asymmetry, (B) border, (C) color, (D)
diameter, and (E) evolving (American Academy of Dermatology, 2018).
If melanoma is not caught before it metastasizes into cutaneous or subcutaneous
tissue the result is a malignancy. In order to treat malignant melanoma specific
molecular changes must be identified in order to use the best treatment therapies.
There are eight different mutations that may occur due to genetic susceptibility. The
mutations include BRAF, NRAS, P13K-ATK/PTEN, p53, CD4K/CDKN2A, c-KIT, MC1R,
and cadherin (Liu et al 2014).
Tumor progression:
1.
Benign melanocytic nevi
2.
Atypical/dysplastic nevi
3.
Radial growth
4.
Vertical growth
5.
Metastasis

Implications of
Nursing Care
•
•
•
•
•
•
•
•
•
•

•
•
•

•
•
•
•
•

•
(McMaster Pathophysiology Review, 2018)

Routine annual physical exams
Nevus count
Monitoring suspicious nevi
In depth familial history
Routine lab workup
Punch biopsy of any suspicious
nevi
Consult to specialists
Use of microscope/dermascope
when evaluating skin
Use of MEDS- and automated
melanoma diagnosis system
Blood assay for those termed
cancer free to predict recurrence of
melanoma
(MITF)- microphthalmia
transcription factor- used to detect
melanoma
History of sunburns with blistering
Education on reducing UV
exposure/ wearing sunscreen and
clothing that covers most of the
skin/eyes.
Education on tanning bed exposure
Education on smoking cessation
Emotional support to those
diagnosed with metastatic
melanoma
Education on best treatment
options and patients age
Expediting care if patient does
come back positive for metastatic
melanoma with biopsy of possible
metastasis
Educating on all signs/symptoms
and risk factors

Using the ABCDE method,
practitioners must know what they are
looking for, any suspicion of melanoma,
or skin cancer must be taken cautiously
and a biopsy should be done. Knowing
the patient physical and social history
will help make the decision easy.
Practitioners must be aware of age if
there is suspicion because “increasing
age leads to worse survival rates in
stages I, II, and III” (Ribero et al, p. 624,
2018).
Health care providers must has
knowledge of the pathyophysiology and
etiology of melanoma in order to
distinguish the signs and symptoms and
diagnose and treat the condition.

Conclusion
Melanoma is a very treatable cancer if
diagnosis and treatment are in the early
stages. In 2014 an estimate of “ nearly
76, 100 new cases of melanoma of the
skin will be diagnosed and about 9,710
people will die due to the disease within
the year alone” (Liu et al, p. 1, 2014). This
makes melanoma one of the fastest
growing cancers in the United States.
The pathophysiology can be technical
when diagnosis of malignant melanoma
and treatment options all depend on age
and the stage of the cancer. Treatment
has become more sophisticated, but
diagnosis and early detection have also
become very specific. Discovering the
specific markers and mutations of
melanoma can allow for early detection
and eliminate the amount of cytotoxic
treatment a patient must receive (Liu et
al, 2014).
The practitioner must force efforts
for education and awareness of the
disease and make it communitywide. The
cost for treating melanoma has increased
significantly, specifically about 250%
(Watson et al, 2015). Early detection and
treatment will decrease morbidity and
mortality rate as well as decrease
unnecessary treatment.
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